세계의 발작 시장 보고서(2025년)
Seizures Global Market Report 2025
상품코드 : 1751109
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,686,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,665,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,644,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

발작 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 6.0%로 성장하여 54억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 신경 장애에 취약한 노인 인구의 증가, 발작 치료제 연구개발 투자 증가, 세계 헬스케어 지출 증가, 간질 치료제 수요 증가, 발작 질환의 유병률 증가 등에 기인하는 것으로 보입니다. 이 기간의 주요 동향으로는 발작 감지 및 모니터링 기기의 발전, 의약품 승인 및 상환 프로세스의 발전, 맞춤형 발작 치료를 위한 유전자 연구의 발전, 원격 모니터링을 위한 디지털 헬스 솔루션의 채택, 간질 치료제의 지속적인 기술 혁신 등을 꼽을 수 있습니다.

외상성 뇌손상(TBI)의 유병률 증가는 발작 시장의 큰 성장을 견인할 것으로 예상되며, TBI는 머리 타격, 충격, 관통 손상과 같은 외력에 의해 발생하며, 고속 충돌 및 옆으로 보는 운전으로 인한 교통 사고의 증가는 더 심각한 머리 손상의 원인이 되고 있습니다. 발작은 종종 TBI의 조기 지표가 되어 의사가 뇌 손상을 보다 효과적으로 진단하고 관리하는 데 도움이 됩니다. 예를 들어, 2023년 10월 사우스다코타주 보건국(SDDOH)의 보고서에 따르면, 2022년 사우스다코타주의 연령 조정 후 TBI 관련 사망률은 미국에서 9번째로 높은 10만 명당 26.4명이었습니다. 또한 미국신경외과학회는 미국에서 연간 170만 명에서 380만 명의 TBI가 발생하는 것으로 추정하고 있습니다. 이러한 외상성 뇌손상 유병률의 증가는 발작 치료제 시장의 성장을 촉진하고 있습니다.

발작 치료제 시장의 주요 업체들은 접근성과 환자 순응도를 높이기 위해 협측 필름과 같은 혁신적인 치료법에 집중하고 있습니다. 협측 필름은 얇고 용해 가능한 스트립으로, 협측 안쪽(협측 점막)에 부착하여 약물이 혈류에 직접 흡수되는 방식으로 투여됩니다. 예를 들어, 2024년 12월 미국 Aquestive Therapeutics Inc.는 미국 FDA로부터 Libervant(디아제팜) 협측 필름의 희귀질환 치료제로 독점 승인을 받았습니다. 리버반트는 2-5세 소아 간질 발작 환자들을 대상으로 하며, 기존의 디아제팜 제제를 대체할 수 있는 비침습적이고 투여하기 쉬운 제제로서 협측 점막을 통한 흡수를 보다 확실하게 보장하는 약물입니다. 이 연령대에서 승인된 최초이자 유일한 경구용 디아제팜 필름으로서 리버반트는 간병인의 편의성을 개선하고 환자의 순응도를 높이는 것을 목표로 하고 있습니다. 이번 승인은 경구용 필름형 간질 치료제 개발 분야에서 아퀘스티브의 입지를 더욱 공고히 하는 계기가 됐습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Seizures are sudden, uncontrolled electrical activities in the brain that can cause changes in movement, behavior, sensation, or awareness. They result from abnormal neuronal activity and can be triggered by conditions such as epilepsy, head injuries, infections, or other medical issues.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug types used to treat seizures are first-generation, second-generation, and third-generation anti-epileptics. First-generation anti-epileptic drugs (AEDs) are the initial class of medications developed for epilepsy treatment. These drugs can be administered through various routes, including oral, parenteral, and topical methods. They are distributed through multiple channels, such as hospital pharmacies, independent pharmacies, and online pharmacies, and are utilized by several end-users, including hospitals, clinics, ambulatory surgical centers, homecare settings, and others.

The seizures market research report is one of a series of new reports from The Business Research Company that provides seizures market statistics, including the seizures industry global market size, regional shares, competitors with the seizures market share, detailed seizures market segments, market trends, and opportunities, and any further data you may need to thrive in the seizures industry. This seizures market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The seizures market size has grown strongly in recent years. It will grow from$3.20 billion in 2024 to $4.35 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to the rising prevalence of epilepsy and seizure disorders, greater awareness and higher diagnosis rates, expanding research and development efforts for neurological conditions, increased government and non-profit initiatives aimed at epilepsy awareness, and the growing geriatric population.

The seizures market size is expected to see strong growth in the next few years. It will grow to$5.49 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to the expanding geriatric population vulnerable to neurological disorders, increased investments in R&D for seizure therapeutics, rising global healthcare expenditure, growing demand for epilepsy medications, and a higher incidence of seizure disorders. Key trends during this period include advancements in seizure detection and monitoring devices, progress in drug approvals and reimbursement processes, breakthroughs in genetic research for personalized seizure treatments, the adoption of digital health solutions for remote monitoring, and ongoing innovations in epilepsy medications.

The increasing prevalence of traumatic brain injuries (TBI) is expected to drive significant growth in the seizures market. TBIs result from external forces, such as blows, jolts, or penetrating injuries to the head, and the rise in road accidents-due to high-speed collisions and distracted driving-has contributed to more severe head injuries. Seizures often serve as an early indicator of TBIs, helping doctors diagnose and manage brain damage more effectively. For example, in October 2023, a report from the South Dakota Department of Health (SDDOH) indicated that in 2022, South Dakota had the 9th highest age-adjusted TBI-related death rate in the U.S. at 26.4 per 100,000. Additionally, the American Association of Neurological Surgeons estimates that between 1.7 million and 3.8 million TBIs occur annually in the U.S. This rising prevalence of traumatic brain injuries is driving the growth of the seizures market.

Leading companies in the seizures market are focusing on innovative treatments such as buccal films to improve accessibility and patient adherence. Buccal films are thin, dissolvable strips that are administered by placing them on the inner cheek (buccal mucosa), where the drug is absorbed directly into the bloodstream. For instance, in December 2024, U.S.-based Aquestive Therapeutics Inc. received U.S. FDA approval for orphan drug exclusivity for Libervant (diazepam) buccal film. This drug is intended for pediatric patients aged two to five with seizure clusters. Libervant offers a non-invasive, easy-to-administer alternative to traditional diazepam delivery methods, ensuring faster absorption through the buccal mucosa. As the first and only orally administered diazepam film approved for this age group, Libervant aims to improve convenience for caregivers and enhance patient compliance. This approval further strengthens Aquestive's position in advancing oral film-based epilepsy therapies.

In March 2022, Belgium-based UCB Pharma acquired U.S.-based Zogenix Inc. for $1.9 billion. With this acquisition, UCB aims to expand its neurology portfolio and enhance treatment options for rare epileptic disorders such as Dravet syndrome and Lennox-Gastaut syndrome. Zogenix is known for developing therapies for rare and serious central nervous system (CNS) disorders, helping UCB strengthen its presence in the epilepsy treatment market.

Major players in the seizures market are Johnson & Johnson Service Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., H. Lundbeck A/S, Zydus Lifesciences Limited, SK Biopharmaceuticals Co. Ltd., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Taro Pharmaceutical Industries Ltd., Marinus Pharmaceuticals Inc., Eton Pharmaceuticals Inc., and Sunovion Pharmaceuticals Inc.

North America was the largest region in the seizures market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in seizures report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the seizures market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The seizures market consists of sales of neurostimulation devices, wearable seizure detection devices, and medical cannabis products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Seizures Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on seizures market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for seizures ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The seizures market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Seizures Market Characteristics

3. Seizures Market Trends And Strategies

4. Seizures Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Seizures Growth Analysis And Strategic Analysis Framework

6. Seizures Market Segmentation

7. Seizures Market Regional And Country Analysis

8. Asia-Pacific Seizures Market

9. China Seizures Market

10. India Seizures Market

11. Japan Seizures Market

12. Australia Seizures Market

13. Indonesia Seizures Market

14. South Korea Seizures Market

15. Western Europe Seizures Market

16. UK Seizures Market

17. Germany Seizures Market

18. France Seizures Market

19. Italy Seizures Market

20. Spain Seizures Market

21. Eastern Europe Seizures Market

22. Russia Seizures Market

23. North America Seizures Market

24. USA Seizures Market

25. Canada Seizures Market

26. South America Seizures Market

27. Brazil Seizures Market

28. Middle East Seizures Market

29. Africa Seizures Market

30. Seizures Market Competitive Landscape And Company Profiles

31. Seizures Market Other Major And Innovative Companies

32. Global Seizures Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Seizures Market

34. Recent Developments In The Seizures Market

35. Seizures Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기